Latest Breaking News On - Merck press releases - Page 3 : comparemela.com

Merck: Glucophage Is the First Oral Diabetes Treatment Approved in Europe for Use During Pregnancy

In a European worksharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth. The approval was granted on the

United statesOliveira baraldiClin pharmacokinetMaria rivasMerck pressWomen healthEuropean healthPublic healthInternational journal of environmental researchNational health statistics reports numberNational health fundJournal of diabetes researchChief medical officerDiab res careTenth editionInternational journal

Merck: New MAVENCLAD Data at ACTRIMS Forum 2022 Show Favourable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression

New real-world data show MAVENCLAD (cladribine tablets) had lower annualised relapse rates and longer time to first relapse and time to switch than fingolimod, dimethyl fumarate and teriflunomide

United statesSouth australiaUnited kingdomHelmut butzkuevenMonash universityMerck pressEuropean commissionAmericas committee for treatmentCentral clinical schoolDepartment of neuroscienceEuropean unionResearch in multiple sclerosisAmericas committeeMultiple sclerosisGenerating learnings in multiple sclerosisCladribine tablets treating

Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma

Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma
q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesCity ofThomas powlesAmerican society of clinical oncologyHead of development unit oncologyMerck pressEuropean commissionDrug administrationQueen mary university of londonSolid tumor research at barts cancer instituteAmerican cancer societyBarts cancer centreUnited kingdom basedClinical oncologyGenitourinary cancers symposium

Merck: Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma

38-month median follow-up data from the Phase III JAVELIN Bladder 100 trial demonstrated prolonged median OS of 23.8 months with BAVENCIO plus best supportive care (BSC) in the first-line maintenance

United statesUnited kingdomCity ofNoelle piscitelliThomas powlesAmerican society of clinical oncologyHead of development unit oncologyMerck pressEuropean commissionDrug administrationQueen mary university of londonSolid tumor research at barts cancer instituteAmerican cancer societyBarts cancer centreUnited kingdom basedClinical oncology

Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).

United statesUnited kingdomBrauti fritzenMerck pressHead of global developmentMyasthenia gravisNeuromyelitis optica spectrum disorderMultiple sclerosisChord therapeuticsDanny bar zoharGlobal developmentOmega fundsMerck press releasesMedia contactScience and technologyChord therapeutics